Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Arzerra (ofatumumab) - Important Safety Information from GlaxoSmithKline (Ireland) Ltd. as approved by the Irish Medicines Board
Notice type:
3rd Party Publications
Date:
20/12/2013
Problem Or Issue:
Important Safety Information communication from GlaxoSmithKline (Ireland) Ltd. on screening all patients for hepatitis B virus before treatment of Arzerra (ofatumumab).
Important Safety Information - Arzerra (ofatumumab)
« Back
Date Printed: 19/05/2024